// STATE LEGISLATION TRACKER

Idaho H703: OCCUPATIONAL AND PROFESSIONAL LICENSING - Amends, repeals, and adds to existing law to revise provisions regarding the D

⚖️ NEUTRAL for peptide users 👤 NONE user impact 📜 Status: Signed

State: Idaho
Bill: H703
Session: 2026
Filed: 2026-02-16
Read the bill: OpenStates →
Last reviewed: 2026-10-02

Plain-English Summary

Idaho H703 is a broad occupational and professional licensing cleanup bill for the Division of Occupational and Professional Licenses. Based on the title, subjects, and available bill text, it does not directly regulate compounded peptides, FDA 503A/503B compounding, off-label prescribing, telehealth, naturopathic scope, controlled substances, or prescription monitoring.

Key Points

No direct peptide access change is apparent
Medical, nursing, and pharmacy boards are touched procedurally
No clear 503A or 503B compounding rule change
No telehealth expansion or restriction is apparent
No naturopathic peptide scope change is apparent

What to Watch For

Note Licensing-board discipline procedures may affect clinicians generally, but not peptide care specifically.

Note Pharmacy-related edits appear procedural, not a new peptide compounding policy.

Note Watch agency rules after July 1, 2026 for any implementation details.

Where the Bill Stands

The bill was signed by the governor on March 27, 2026, became Session Law Chapter 221, and takes effect July 1, 2026.

· Ed. Our analysis pulls public bill metadata from OpenStates and is enriched with research-model context. We don't quote bill text we haven't read directly. If this bill matters to your practice or treatment access, read the official source linked above before taking action. We're an educational research directory, not a legal or medical reference.

Bill page generated 2026-11-04 · enriched via codex gpt-5.5
Source: OpenStates v3 API · View official bill · ← back to all laws